Medix Biochemica

Medix Biochemica is an independent, international, and industry-leading supplier of in vitro diagnostics raw materials with Finnish origins and a global presence. The company specializes in producing and delivering high-quality antibodies, antigens, and other essential IVD raw materials. Medix Biochemica's offerings support IVD customers worldwide in manufacturing diagnostic tests across various market segments, including immunoassay, clinical chemistry, and molecular diagnostics. The company's capabilities extend to biospecimen accruals and contract manufacturing, making them a comprehensive solution provider in the IVD sector. With the broadest raw material portfolio and a team comprised of top-notch professionals, Medix Biochemica is dedicated to expediting time-to-market and ensuring quality in every test. Regardless of the discipline or disease area, they have the expertise to meet diverse IVD needs.

History

In 1985, Medix Biochemica was founded in Finland, initially focusing on the industrial-scale production of monoclonal antibodies. Over the years, the company expanded its global footprint:

2016: Medix Biochemica China was established to provide local services for the Chinese IVD industry.

2018: Medix Biochemica USA was established to offer local services to North American customers.

2019: Lee Biosolutions was acquired, adding world-leading products and expertise in native proteins to their portfolio.

2020: Acquisitions of EastCoast Bio and Biostride significantly increased the availability of antibodies and antigens, especially for drugs of abuse, veterinary, and infectious diseases testing.

2021: The establishment of MedixMDx and the acquisition of Diaclone kickstarted the molecular diagnostics offering, along with unique antibodies and assays for immuno-oncology and inflammation.

2022: Acquisitions of myPOLS Biotec & Bioresource Technology further extended the diagnostics offering and broadened base matrix capabilities.

Capabilities

Medix Biochemica's investment in technologies ensures the highest quality monoclonal antibodies. The company has expanded its portfolios and capabilities, positioning itself as a global, market-leading IVD supplier. They offer customized contract manufacturing services, streamlining antibody production through processes such as evaluation, optimization, cell line adaptation, mycoplasma testing, production optimization, and validation.

Molecular Diagnostics

Collaborating with customers worldwide, Medix Biochemica develops molecular diagnostics solutions for infectious diseases, genetic testing, personalized medicines, drug discovery, blood screening, veterinary, and environmental applications. The MedixMDx team's expertise covers every aspect of molecular diagnostics development and manufacturing, supporting clients from concept to commercialization and expediting assay development time and complexity.

Experience and Innovation

With over 30 years of experience, Medix Biochemica has developed numerous hybridoma cell lines and highly specific, potent monoclonal antibodies. The company has intensified investments in research and development and adopted new technological innovations, offering state-of-the-art technologies in antibody and enzyme development.

Search for products by Medix Biochemica